BiotechTube

AG013

Phase 2Terminated
3 views this week 0 watching💤 Quiet
Interest: 17/100
17
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Oral Mucositis

Conditions

Oral Mucositis

Trial Timeline

Jul 18, 2017 → Jul 13, 2020

NCT ID
NCT03234465

About AG013

AG013 is a phase 2 stage product being developed by Oragenics for Oral Mucositis. The current trial status is terminated. This product is registered under clinical trial identifier NCT03234465. Target conditions include Oral Mucositis.

What happened to similar drugs?

5 of 20 similar drugs in Oral Mucositis were approved

Approved (5) Terminated (2) Active (14)
❌AL001 + Placebo + Open label - AL001AlectorPhase 3
🔄Micafungin + FluconazoleAstellas PharmaPhase 3
🔄micafungin + caspofunginAstellas PharmaPhase 3
🔄Erlotinib + PlaceboAstellas PharmaPhase 3
✅AmifostineSun PharmaceuticalApproved
🔄Teriparatide 20 mcgEli LillyPhase 3
✅tramadol hydrochloride + acetaminophenJohnson & JohnsonApproved

Hype Score Breakdown

Clinical
12
Activity
0
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03234465Phase 2Terminated

Competing Products

20 competing products in Oral Mucositis

See all competitors
ProductCompanyStageHype Score
AL001 + Placebo + Open label - AL001AlectorPhase 3
22
AL001AlectorPhase 2
25
LP-10 (Liposomal Tacrolimus)Lipella PharmaceuticalsPhase 2
29
Micafungin + FluconazoleAstellas PharmaPhase 3
40
micafungin + caspofunginAstellas PharmaPhase 3
40
Erlotinib + PlaceboAstellas PharmaPhase 3
40
AmifostineSun PharmaceuticalApproved
35
exenatide + Other antidiabetic therapiesEli LillyPre-clinical
26
Teriparatide 20 mcgEli LillyPhase 3
40
LY3884963 + Methylprednisolone + Optional Sirolimus + Optional PrednisoneEli LillyPhase 1/2
36
Baricitinib 4 milligram Oral TabletEli LillyPhase 2
39
tramadol hydrochloride + acetaminophenJohnson & JohnsonApproved
43
Essential oils + 0.2% chlorhexidine + Sterile waterJohnson & JohnsonApproved
43
galantamine hydrobromideJohnson & JohnsonPhase 2
35
HR17031 injection + insulin glargineJiangsu Hengrui MedicinePhase 3
40
Camrelizumab + Camrelizumanb plus TPFJiangsu Hengrui MedicinePhase 2
35
Camrelizumab plus TP + TPJiangsu Hengrui MedicinePhase 3
47
AZD1981 + Neovletta 21/28 + Placebo AZD1981AstraZenecaPhase 1
29
DurvalumabAstraZenecaPhase 1/2
36
fostamatinib + Microgynon® 30 (Oral contraceptive) + PlaceboAstraZenecaPhase 1
29